CN Patent

CN113365624A — 用于治疗淋巴瘤或t-细胞恶性疾病的化合物

Assigned to Mundi Pharmaceutical International Co ltd · Expires 2021-09-07 · 5y expired

What this patent protects

本发明涉及在淋巴瘤或T细胞恶性疾病的治疗中使用的替诺莫司汀(tinostamustine)。当施用至患者时，替诺莫司汀可能会引起副作用，并且期望将这样的副作用最小化。本发明限定了一种改进的治疗，其中所施用的替诺莫司汀的剂量基于患者的血小板计数而变化。

USPTO Abstract

本发明涉及在淋巴瘤或T细胞恶性疾病的治疗中使用的替诺莫司汀(tinostamustine)。当施用至患者时，替诺莫司汀可能会引起副作用，并且期望将这样的副作用最小化。本发明限定了一种改进的治疗，其中所施用的替诺莫司汀的剂量基于患者的血小板计数而变化。

Drugs covered by this patent

Patent Metadata

Patent number
CN113365624A
Jurisdiction
CN
Classification
—
Expires
2021-09-07
Drug substance claim
No
Drug product claim
No
Assignee
Mundi Pharmaceutical International Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.